Treatment strategies for @entity256 : systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 XXXX .

@entity1 @entity75 @entity8038 @entity256 @entity299 @entity583 @entity204 @entity715
STUDY QUESTION: What is the most safe and effective interventional treatment for @entity256 ? METHODS: In a hierarchical Bayesian network meta-analysis, PubMed, Embase, Scopus, Cochrane Library, Web of Science, ScienceDirect, and major scientific websites were screened up to 10 August 2015. Randomised controlled trials of @entity1 with any type of @entity256 (either of bare metal stents or drug eluting stents; and either first or recurrent instances) were included. Trials including multiple treatments at the same time in the same group or comparing variants of the same intervention were excluded. Primary endpoints were @entity75 revascularisation and late lumen loss, both at six to 12 months. The main analysis was complemented by network subanalyses, standard pairwise comparisons, and subgroup and sensitivity analyses. STUDY ANSWER AND LIMITATIONS: Twenty four trials (4880 @entity1 ), including seven interventional treatments, were identified. Compared with plain balloons, bare metal stents, brachytherapy, rotational atherectomy, and cutting balloons, @entity8038 and drug eluting stents were associated with a reduced risk of @entity75 revascularisation and major adverse @entity299 , and with reduced late lumen loss. Treatment ranking indicated that drug eluting stents had the highest probability (61.4%) of being the most effective for @entity75 vascularisation; @entity8038 were similarly indicated as the most effective treatment for late lumen loss (probability 70.3%). The comparative efficacy of @entity8038 and drug eluting stents was similar for @entity75 revascularisation (summary odds ratio 1.10, 95% credible interval 0.59 to 2.01) and late lumen loss reduction (mean difference in minimum lumen diameter 0.04 mm, 95% credible interval -0.20 to 0.10). Risks of @entity204 , @entity583 , and stent @entity715 were comparable across all treatments, but these analyses were limited by a low number of events. Trials had heterogeneity regarding investigation periods, baseline characteristics, and endpoint reporting, with a lack of information at long term follow-up. Direct and indirect evidence was also inconsistent for the comparison between drug eluting stents and @entity8038 . WHAT THIS STUDY ADDS: Compared with other currently available interventional treatments for @entity256 , @entity8038 and drug eluting stents are associated with superior clinical and angiographic outcomes, with a similar comparative efficacy. FUNDING, COMPETING INTERESTS, DATA SHARING: This study received no external funding. The authors declare no competing interests. No additional data available.
